WALTHAM, Mass., Feb. 12, 2015 (GLOBE NEWSWIRE) — Eyegate Pharmaceuticals, Inc. (OTCQB:EYEGV) (“EyeGate”), a specialty pharmaceutical company that focuses on developing and commercializing therapeutics and drug delivery systems for treating diseases of the eye, today announced the pricing of its initial public offering of 683,250 shares of its common stock, offered at a price to the public of $6.00 per share. The gross proceeds to EyeGate from this offering are expected to be approximately $4,100,000 before deducting underwriting discounts and other estimated offering expenses. EyeGate has granted the representative of the underwriters a 45-day option to purchase up to 102,487 additional shares of its common stock to cover over-allotments, if any. The shares are expected to begin trading on the OTCQB Venture Marketplace under the symbol “EYEGV” on February 13, 2015 and the offering is expected to close on February 19, 2015, subject to customary closing conditions.
Aegis Capital Corp. and Chardan Capital Markets, LLC are acting as the joint book-running managers for the offering.
A registration statement on Form S-1 filed with the Securities and Exchange Commission (the “SEC”) was declared effective on February 12, 2015.
The offering is being made only by means of a prospectus. Copies of the final prospectus relating to this offering will be filed with the SEC and may be obtained, when available, by contacting Aegis Capital Corp, Prospectus Department, 810 Seventh Avenue, 18th Floor, New York, NY 10019, telephone: 212-813-1010, email: prospectus@aegiscap.com. Investors may also obtain these documents at no cost by visiting the SEC’s website at http://www.sec.gov.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
About EyeGate
EyeGate is a clinical-stage specialty pharmaceutical company that is focused on developing and commercializing therapeutics and drug delivery systems for treating diseases of the eye. EGP-437, the company’s first and only product in clinical trials, incorporates a reformulated topically active corticosteroid, dexamethasone phosphate, that is delivered into the ocular tissues through EyeGate’s proprietary innovative drug delivery system, the EyeGate® II Delivery System. For more information, please visit www.EyeGatePharma.com.
Lee Roth / Joseph GreenThe Ruth Group for EyeGate Pharmaceuticals646-536-7012 / 7013